Point72 Asset Management L.P. grew its stake in Puma Biotechnology Inc (NASDAQ:PBYI) by 265.6% during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 482,200 shares of the biopharmaceutical company’s stock after purchasing an additional 350,300 shares during the quarter. Point72 Asset Management L.P. owned approximately 1.28% of Puma Biotechnology worth $57,743,000 as of its most recent filing with the SEC.

Several other institutional investors also recently modified their holdings of the company. New York State Common Retirement Fund boosted its holdings in shares of Puma Biotechnology by 4.7% in the second quarter. New York State Common Retirement Fund now owns 32,247 shares of the biopharmaceutical company’s stock valued at $2,818,000 after acquiring an additional 1,446 shares in the last quarter. Teacher Retirement System of Texas purchased a new stake in Puma Biotechnology in the 2nd quarter worth approximately $211,000. BlackRock Inc. lifted its position in Puma Biotechnology by 5.0% in the 2nd quarter. BlackRock Inc. now owns 1,830,342 shares of the biopharmaceutical company’s stock worth $159,973,000 after buying an additional 86,924 shares in the last quarter. Prudential Financial Inc. purchased a new stake in Puma Biotechnology in the 2nd quarter worth approximately $302,000. Finally, Alliancebernstein L.P. lifted its position in Puma Biotechnology by 5.1% in the 2nd quarter. Alliancebernstein L.P. now owns 41,140 shares of the biopharmaceutical company’s stock worth $3,596,000 after buying an additional 2,000 shares in the last quarter. Institutional investors and hedge funds own 96.05% of the company’s stock.

Puma Biotechnology Inc (NASDAQ:PBYI) opened at $101.15 on Tuesday. Puma Biotechnology Inc has a 12 month low of $28.35 and a 12 month high of $136.90.

Puma Biotechnology (NASDAQ:PBYI) last posted its earnings results on Thursday, November 9th. The biopharmaceutical company reported ($2.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.50) by $0.43. The firm had revenue of $6.10 million during the quarter, compared to analyst estimates of $3.78 million. During the same quarter in the previous year, the business posted ($1.11) earnings per share. sell-side analysts anticipate that Puma Biotechnology Inc will post -8.19 earnings per share for the current year.

In other Puma Biotechnology news, insider Charles R. Eyler sold 1,322 shares of the stock in a transaction on Friday, December 1st. The shares were sold at an average price of $105.46, for a total value of $139,418.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Richard Paul Bryce sold 15,000 shares of the stock in a transaction on Friday, September 29th. The shares were sold at an average price of $120.00, for a total transaction of $1,800,000.00. Following the completion of the sale, the senior vice president now directly owns 42,239 shares of the company’s stock, valued at $5,068,680. The disclosure for this sale can be found here. Company insiders own 21.10% of the company’s stock.

PBYI has been the subject of a number of research analyst reports. Bank of America reiterated a “buy” rating and issued a $135.00 target price (up previously from $117.00) on shares of Puma Biotechnology in a research report on Monday, October 9th. Citigroup reiterated a “buy” rating and issued a $156.00 target price (up previously from $114.00) on shares of Puma Biotechnology in a research report on Thursday, October 5th. J P Morgan Chase & Co reiterated a “buy” rating and issued a $131.00 target price on shares of Puma Biotechnology in a research report on Wednesday, October 4th. BidaskClub upgraded shares of Puma Biotechnology from a “hold” rating to a “buy” rating in a research report on Friday, September 8th. Finally, Stifel Nicolaus increased their target price on shares of Puma Biotechnology from $110.00 to $130.00 and gave the stock a “buy” rating in a research report on Monday, October 2nd. One research analyst has rated the stock with a sell rating, one has given a hold rating and nine have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $130.67.

ILLEGAL ACTIVITY NOTICE: “Puma Biotechnology Inc (PBYI) Holdings Boosted by Point72 Asset Management L.P.” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2017/12/12/puma-biotechnology-inc-pbyi-holdings-boosted-by-point72-asset-management-l-p.html.

Puma Biotechnology Profile

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.

Institutional Ownership by Quarter for Puma Biotechnology (NASDAQ:PBYI)

Receive News & Stock Ratings for Puma Biotechnology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology Inc and related stocks with our FREE daily email newsletter.